would and to deliver and another to good Matthew, hard like helping us all. continuing act owners I morning our to to record by and Thanks, in thanking employees dedication begin like acknowledging work, their for think QX. and quarter
on our prepared are QX of full environment, execution to constantly we're solid conditions macroeconomic demonstrating the X. we our delivered remain strength on Starting XXXX the performance, raising And to Despite change. market We if nimble, year engine start our changing year, guidance. based were another team Slide our the pivot continued IRX. and solid to
to Slide X. Turning
is expect continue like to and our update in Our above-market economic to provide this to mindset, IRX we growth combined brief in unique committed page. long-term I deliver initiatives. Day growth that targets We to XXXX. our growth results. a our outlined would competitive with strategy our our differentiator. ownership With Investor continues to remain on compounding And on engine deliver mind,
inorganic let On highlight start Slide initiatives. two with We're to closed recently growth transactions. X, pleased me our
you In adjacent words, two that both are me companies' other pump deals walk our be or core. attaching used them our products to these through can technologies. Let existing compressor to by
extending First, by our attractive reach addition highly markets sterile Ethafilter, with end which our filtration technology. expands into of the technology
expands aerospace and assembly our thermoplastics, Next specialization technology applications. bonding plastic plastic is high-performance and custom industrial which sciences, life for Controlled Fluidics, in with products
right-hand highlight inorganic annualized have this I of the side later announced is strategy be like expected which target our to close quarter, page, M&A in on the inorganic would our the to to to already of exceeded acquisition revenue we annualized finally, XXX ILC target. basis later points. And we that of with continue Dover, bolt-on revenue expect Having deals year, execute the announced more that, to said XXX and exceeding further our
slide details competencies core additional X. opportunities. of This of provide with and future an each end for the to the of breakdown market the acquisition portion as Turning growth overview the of information the Dover by ILC well long-term some on want creation business, business Slide I as to CAGR portfolio. the
and XX-XX total which the roughly business Approximately markets split XX% key be life between medical of falls components/CDMO. market end biopharma into can sciences of
plus to long high expect in over grow the single-digit range term. the business of We portion this the
customer these as powder handling, future access core direct dive a biopharma, and as the Let and are compressors customers. which in pumps and channel for see in we with competencies growth me opportunities to where starting liquid pull-through deeper, well bit new the on
cancer support in supplying to of in treat Dover the and has technologies Some of in monoclonal diseases. therapeutics cell market. great manufacturing plays drivers novel where culture market and diabetes serve markets biopharma crucial the of cell growth is facilities a gene the the fast-growing to in Dover and for next-generation the obesity the and most presence demand growing in antibody role increase ILC containment antibodies exciting ILC also therapy flexible in and derivatives for rare therapies single-use and
a in footprint single-use The and reduce our core solutions. capital support play Ingersoll and much sterilization risk, all manufacturing how to by primary we times current is and the customer cleaning batch benefits a investment, for which reduced role the process, which an planned products ROI ILC Rand customers equipment Dover and shorter are produced respectively, lower turnaround cross-contamination flexible efforts, of important at highly our with
the to medical is as complex portion components to custom the of silicon extrusion medical and the on well business, business us competency of thermoplastic the technology molding sub-assemblies. of as where and This a gives on cardiovascular neurology. components/CDMO and range segments Moving focusing new like access high-growth customers wide core side,
creation growth the systems for high items opportunities well this tubing leverage as future on compression pull-through the of business, lot and niche a pumps the produce subassemblies see they like we to addition, of biopharma for as in consumable In technology today.
business the Moving multiple XX% defense for our end and which market, of accounts the nature, portfolio small very total for to have although approximately excited aerospace on we're within in reasons. this business, to
us XXXX. growth very the has global into given entry and $XXX business a nearly be from profitability. market, point in billion in is a trillion of is $X.X of this And XXXX, worth First, to tripling estimated by second, great space it solid terms which
As the described on majority the volume of comprised and of mobility slide, is human the habitation.
opportunity mid-single technologies of growth suits, air vehicles market, lighter Over believe and habitats, we single-digit an inflatable core space core and we a the a inflatables, other for there that high is to opportunity. competency in term, future rate. With on our growth end long this pull-through anticipate and
additional we're not some present. perspective generation where provide And across we for oxygen on in this market one needed today how example oxygen the a our we're For portable these of all technology And is leader just technologies compression see example, products. currently to concentrators. is pull-through
As strategic M&A. X, Slide me to of against talking time let about for spend alignment some the importance we our ILC Dover move stated
technologies. with example an adjacent of start we First,
is the life targeted containment, which adjacent offer protectors With powder always Within of build our focuses one is of others. support product example tubing can Dover, complete steps across in ILC by combining combine are management, technology devices consumable example our consumables get single-use including components, of with more exactly market also peristaltic the customers end and liquids on ILC market, deliver their we many a made bioprocessing, we biopharma tubing portion a workload. newly our isolator which clear ILC we liquid single-use and which help Dover to can launched to pumps how this to the have we technology pump technology, portfolio customers.
An very merely multiple Dover. This to and that, science within
Moving into the aligned category.
made best-in-class, it we're like one cancer. potency for conjugates, Dover ADCs, treat biopharma First, and essential Isolators antibody is and or manufacturing. by biopharmaceutical mission-critical fast-growing requiring are manufacturing of ILC a isolators which flexible high target to of step therapies drugs an designed in the single-use APIs, drug which equipment getting class process of is
biomanufacturing. business fragmented high-growth enabled Second, highly us and of a enter tech med segment the to medical components/CDMO
them. and on for communication compression on the a also direct mentioned significant pumps with pull-through and existing believe our new a there opportunity and channel previous access As that of slide, customers technology is we to
larger for the market Dover's of many we Rand's aerospace Dover and aerospace and optionality with on defense. us defense, to pull-through build a creation The has Ingersoll our deep given Dover NASA, opportunities ILC acquisition optionality to market ILC technologies. to us and existing to relationships Boeing with Sierra relationship Finally, fast-growing fast-growing of business life bolt-on sciences platform we of leverage continue and these now Space, the through access a provides can that name flow the few, of with ILC just believe M&A
X. to Moving Slide
organic organic orders due touch down timing. me quarter large the to in were base primarily on X%, Let order first our project Total a initiatives.
of building an which to up focused saw quarter. discussed X% we and can we're we project outsized As we loan projects, year-over-year. a tend that have projects getting lumpy usually book-to-bill. in in on a single to these backlog, investments tough as believe expected, be was book-to-bill We cycle X%, And large share of than nature. by In driven dynamic this comparisons QX, create be before, mega continue greater
the acceleration through to order the side left the and the QX second on quarter. chart the Moving of increased qualified organic by both page, leads the half marketing encouraged activity the we're in of MQL or
the sequential throughout orders side page, orders saw On as X% order January XX% compared saw illustrate March organic of to quarter. we the February. left-hand versus sequentially were February the we up and sequential the growth
backlog quarter, in book-to-bill with above was Consistently in to targets. growth initial our X guidance, continue of organic support build the at our X.XXx
project and earnings last call, due our we order timing. some mentioned tough large XXXX As cycle comps to very on had QX had long
a For orders remain positive. stack, organic X-year
now page, up year-over-year to illustrate activity X% this QX MQLs year. growth QX hand our XXXX, and acceleration throughout finished Moving the In in of of the the is first prior we this year. quarter top X% of the of right on side MQL
to by sequential We the to with conditions second as we remain do MQLs changing conditions. pivot the in and half acknowledge MQLs and half the constantly the market in throughout We saw of during market nimble quarter, compared we where momentum remain encouraged quarter an are quarter. increase changing, the XX% first that of prepared those
on update QX over turn the performance. our now to an financial provide to will I presentation Vik
